7T MRI for Light Therapy in Patients With Mild Cognitive Impairment and Mild AD

Prior treatment

• Those taking sleep medication will be not included
• obstructing cataracts, macular degeneration, and blindness
  • o Those who have undergone cataract surgery and received an intraocular lens coated with ultraviolet- and blue-blocking filters (400-440/440-500 nm) will also be excluded
• 7T MRI specific exclusions including presence of metallic or biomedical implants (patients can be enrolled at the discretion of the study team and site MRI technicians) and claustrophobia

Other illness

• Presence of another brain disease that fully explains the dementia (extensive brain vascular disease, Parkinson's disease, dementia with Lewy bodies, traumatic brain injury, or multiple sclerosis)
• indication for psychiatric hospitalization or acute suicidality in the opinion of the physician
• major organ failure (e.g., kidney failure)
• uncontrolled generalized disorders such as hypertension or diabetes
• severe sleep apnea:
  • o Apnea will be screened for using the Sleep Apnea scale of the Sleep Disorders Questionnaire (SA-SDQ), a 12-item scale yielding scores between 0 and 60.3. The study will use a score of 29 as a cutoff for men (sensitivity 75%, specificity 65% for sleep apnea), and a cutoff of 26 for women (sensitivity 80%, specificity 67%).
• restless leg syndrome (RLS):
  • o RLS will be screened for using the International Restless Legs Scale (IRLS), a 10-item scale that yields scores between 0 and 40.4 The study will use a cutoff of greater than or equal to 11 (indicating the presence of symptoms that are at least moderate) as a positive screen for RLS
• history of:
  • severe photosensitivity dermatitis
  • severe progressive retinal disease (e.g., macular degeneration), or;
  • a permanently dilated pupil (e.g., after certain types of cataract surgery)

Other

• residence in a skilled nursing facility or long-term care
• recent changes in psychotropics (14 days)

• the patients must have undergone PET scans to measure amyloid protein accumulation within the past year
• Those taking antidepressants will be included, but type of medicine and dosage intake will be monitored.
• 50 years and older
• Eligible participants will be amnestic mild cognitive impairment (MCI) or mild Alzheimer's disease (AD) patients with circadian sleep disturbances who reside in their homes, independent living, or assisted living facilities.
• confirmed amyloid beta positive from an existing ADRC cohort with PET scan (age: 50-85 yrs, 40% M, 60% F; falling between 0.5-4.0 and 4.5-9.0 in the Clinical Dementia Rating Scale Sum of Boxes (CDR-SOB)